Replies to post #241601 on Biotech Values

[dewophile]

This was supposed to be a biggie in the pipeline for GSK. They can't seem to get anything right these days. Maybe the HIF inhibitor can hit it big if safety is better than FGEN and AKBA, which was not even talked about a few years ago bc it was not in one of their "core areas"?
I am not surprised Hal Barron jumped ship

[DewDiligence]

Re: Maternal RSV vaccines

On today’s investor CC, PFE executives were asked why they aren’t concerned about the safety of their maternal RSV vaccine (to protect newborns) given that GSK encountered a safety problem with their maternal RSV vaccine and ended up terminating the program (#msg-168031601).

The reply was that no safety signal was seen in PFE’s maternal trial and that PFE didn’t have any information on what caused the problem in GSK’s program (which might not be the truth, the whole truth, and nothing but the truth).